GlaxoSmithKline Collaborates with National Cancer Institute to Make Large Body of Cancer Cell Genomic Data Available to All Cancer R...(rested researchers can download this fre...),Health

About GlaxoSmithKline

GlaxoSmithKline -- one of the world's leading research-based pharmaceutical and healthcare companies -- is committed to improving the quality of human life by enabling people to do more, feel better, and live longer. For company information, visit GlaxoSmithKline at http://www.gsk.com.

GSK in Oncology

GSK Oncology is dedicated to producing innovations in cancer that will make profound differences in the lives of patients. Through GSK's revolutionary "bench to bedside" approach, we are transforming the way treatments are discovered and developed, resulting in one of the most robust pipelines in the oncology sector. Our worldwide research in oncology includes collaborations with more than 160 cancer centers. GSK is closing in on cancer from all sides with a new generation of patient focused cancer treatments in prevention, supportive care, chemotherapy and targeted therapies.

About caBIG(TM)

The National Cancer Institute's cancer biomedical Informatics Grid(TM) (caBIG(TM)) is an information network that enables data and knowledge to be shared within and across organizations, scientific domains, and countries to accelerate the discovery of new approaches for the detection, diagnosis, treatment, and prevention of cancer. Cancer centers, research facilities, and other organizations from across the country are already getting connected with caBIG(TM), and caBIG(TM)-compatible tools and infrastructure are being adopted throughout the cancer and biomedical community. https://cabig.nci.nih.gov/